Adimune (ADi-001/002)

About Aditxt

Aditxt is a U.S.-based biotech firm developing technologies to monitor and modulate the immune system through its two core platforms: AditxtScore for immune profiling and Adimune for inducing immune tolerance. Its mission is to translate immune insights into therapies for autoimmune disorders and transplant rejection, with a pipeline primarily in preclinical and early clinical stages. The company faces significant challenges, including extreme stock volatility indicative of financial distress, a pre-revenue status requiring continual capital, and the high-risk nature of developing novel immunology platforms in a crowded competitive landscape.

Therapeutic Areas

Other Type 1 Diabetes Drugs